Statement: Participants in cohort 1 of the primary trial weighing less than 45 kg receive 4 million units/m^2 less of IL-2, than participants over 45 kg, but all participants will be administered IL-2 3 times per week for 6 doses.
Primary_evidence: INTERVENTION 1:    Arm 1: CsA   Fludarabine: Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).   Cyclophosphamide: Administered intravenously, 60 mg/kg, days -5 and -4. Cyclosporine (CsA): Administered intravenously, 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14   Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given.   Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses). INTERVENTION 2:    Arm 2: CsA/Methylprednisolone (10mg)/6 Doses of Interleukin-2   Fludarabine: Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).   Cyclophosphamide: Administered intravenously, 60 mg/kg, days -5 and -4. Cyclosporine (CsA): Administered intravenously, 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14   Natural Killer cells: Administered by infusion over less than 1 hour; no more than 8.0 x 10^7 cells/kg will be given.   Interleukin- 2 (IL-2): Given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, IL-2 will be given at 5 million units/m^2 3 times per week for 6 doses). Methylprednisolone: Administered intravenously,10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9.